Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1990 2
1991 1
1994 1
1995 1
1996 1
1998 1
2001 1
2004 1
2008 2
2010 2
2011 1
2012 1
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, Morgan MA. Parsels LA, et al. Among authors: zabludoff sd. Clin Cancer Res. 2011 Jun 1;17(11):3706-15. doi: 10.1158/1078-0432.CCR-10-3082. Epub 2011 Apr 11. Clin Cancer Res. 2011. PMID: 21482692 Free PMC article.
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.
Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, Gero T, Glynn RE, Horn CL, Ioannidis S, Lyne P, Newcombe NJ, Oza VB, Pass M, Springer SK, Su M, Toader D, Vasbinder MM, Yu D, Yu Y, Zabludoff SD. Janetka JW, et al. Among authors: zabludoff sd. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4242-8. doi: 10.1016/j.bmcl.2008.05.016. Epub 2008 May 6. Bioorg Med Chem Lett. 2008. PMID: 18547806
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS. Morgan MA, et al. Among authors: zabludoff sd. Cancer Res. 2010 Jun 15;70(12):4972-81. doi: 10.1158/0008-5472.CAN-09-3573. Epub 2010 May 25. Cancer Res. 2010. PMID: 20501833 Free PMC article.
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM. Zabludoff SD, et al. Mol Cancer Ther. 2008 Sep;7(9):2955-66. doi: 10.1158/1535-7163.MCT-08-0492. Mol Cancer Ther. 2008. PMID: 18790776 Free article.
19 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page